CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
September 2022—The FDA has cleared the BioMérieux Vidas Nephrocheck assay to detect kidney stress in patients at risk of acute kidney injury.
The Nephrocheck test detects kidney stress prior to actual damage and is intended to be used in conjunction with clinical evaluation as an aid to support the risk assessment of moderate or severe AKI in patients who are acutely ill. Nephrocheck test kits are FDA cleared on the Astute140 meter (Astute Medical) and Vidas 3 instrument. The Vidas Nephrocheck test will be available in the United States next year.
Pages: 1 2